just a note of caution amongst the euphoria around this share... 1) nefiracetam is not, and never will be, a world-beater with a mediocre effect only in a small spectrum of post-CVA dysfunction. The journal the seminal study was reported in gives a reasonable assessment of the medical opinion of the results. For it to ever be licenced in the only market that counts - the US - it will need a much larger (and much more expensive) clinical trial, and I can't see a major pharma company banging on the door to get hold of this drug to incur the costs themselves. 2) all of the other medications are at relatively early stage of clinical testing, in a clinical area absolutely littered with previous failures. Believe me, I have watched this area for the best part of 2 decades. And I'm sorry to say that efficacy in rats uncommonly translates to efficacy in humans. Therefore, to speculate in this share in the midst of euphoria is one thing, but to assume that it represents a strong likelihood of future success is very much another. Hopefully, as a small NZ biotech company, they are successful, but overall the likelihood is less than 50%.
NEU Price at posting:
3.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)